Dermatologic adverse events in EGFR-TKIs: A real-world analysis

被引：0
|
作者：
Paton, Emily [1 ]
Friedman, Ryan Jeremy [1 ]
Cetnar, Jeremy Paul [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20572
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adverse events related to EGFR-TKIs: UK guidelines
    [J]. Reactions Weekly, 2015, 1563 (1) : 8 - 8
  • [2] Rates and Economic Burden of Adverse Events in Patients With Metastatic NSCLC Treated with EGFR-TKIs
    Subramanian, J.
    Laliberte, F.
    Fernandes, A.
    Pavilack, M.
    Jacques, P.
    Duh, M. S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S827 - S827
  • [3] The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
    Yu, Xiaoqing
    Si, Jinfei
    Wei, Jingwen
    Wang, Yanling
    Sun, Yan
    Jin, Jianan
    Zhang, Xiaoyan
    Ma, Tonghui
    Song, Zhengbo
    [J]. CANCER MEDICINE, 2023, 12 (05): : 5630 - 5638
  • [4] A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma
    Xue Han
    Lan Liang
    Chenming He
    Qinyou Ren
    Jialin Su
    Liang Cao
    Jin Zheng
    [J]. BMC Complementary Medicine and Therapies, 23
  • [5] A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma
    Han, Xue
    Liang, Lan
    He, Chenming
    Ren, Qinyou
    Su, Jialin
    Cao, Liang
    Zheng, Jin
    [J]. BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [6] Real-world rates and costs of EGFR-TKI-related adverse events
    [J]. Reactions Weekly, 2018, 1724 (1) : 9 - 9
  • [7] Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data
    Ito, Kentaro
    Murotani, Kenta
    Kubo, Akihito
    Kunii, Eiji
    Taniguchi, Hirokazu
    Shindoh, Joe
    Asada, Kazuhiro
    Imaizumi, Kazuyoshi
    Takahashi, Kosuke
    Karayama, Masato
    Okuno, Motoyasu
    Inui, Naoki
    Hataji, Osamu
    Morikawa, Sayako
    Hayai, Shunsaku
    Suda, Takafumi
    Abe, Takashi
    Tsuda, Takeshi
    Yamagichi, Teppei
    Kimura, Tomoki
    Oya, Yuko
    Yoshida, Tatsuya
    Hida, Toyoaki
    [J]. CANCER SCIENCE, 2020, 111 (10) : 3705 - 3713
  • [8] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study
    Wu, F.
    Wu, S. X.
    Hu, H. C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [9] Osimertinib versus First-Generation EGFR-TKIs in Untreated EGFR-Mutant NSCLC with Brain Metastasis: 362 Real-World Cases
    Zhao, Y.
    Li, S.
    Zhu, Z.
    Ni, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S624 - S625
  • [10] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study
    Hu, Chunhong
    Wu, Sixuan
    Deng, Renfang
    Wu, Yuanqiang
    Pan, Yue
    Shu, Long
    Wu, Fang
    [J]. CANCER MEDICINE, 2023, 12 (01): : 266 - 273
12345